Form 4: Neurocrine Officer's RSU Vesting, Tax Withholding

Neurocrine Biosciences' Chief Regulatory Officer, Ingrid Delaet, reported the vesting of 801 restricted stock units and the withholding of 475 shares for tax obligations.

Summary

• Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences Inc. (NBIX), reported transactions related to her equity holdings.
• On January 31, 2026, 801 restricted stock units (RSUs) vested, converting into 801 shares of common stock.
• Concurrently, 475 shares of common stock were withheld by the company to cover tax withholding requirements associated with the RSU vesting.
• The price at which shares were withheld for tax purposes was $136.06 per share.
• Following these transactions, Ingrid Delaet beneficially owns 5,056 shares of Neurocrine Biosciences common stock.
• The RSU award was originally granted on January 31, 2022, with vesting tranches occurring annually from 2023 to 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting routine executive compensation and the successful vesting of equity awards, which aligns the officer's interests with shareholders.

Positives

• Vesting of 801 restricted stock units (RSUs) for Ingrid Delaet, indicating a successful compensation event for the officer.
• The company facilitated tax obligations by withholding shares, a common and efficient practice for RSU vesting.

Negatives

• No direct negatives for the company or investors are indicated in this routine insider transaction report.

Risks

• No specific risks to the company are mentioned in this Form 4 filing, which primarily reports insider transactions.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• No direct quotes or paraphrased statements from company management are included in this Form 4 filing.

Industry Context

StockSavvy.ai notes that RSU vesting and subsequent tax withholding are standard practices in executive compensation across the biotechnology and pharmaceutical industries. This routine transaction reflects the normal course of equity compensation for a Chief Regulatory Officer at a publicly traded company like Neurocrine Biosciences.

Comparison to Industry Standards

• This transaction is a standard equity compensation event, common across publicly traded companies, particularly in the biotech sector.
• It aligns with typical executive compensation structures where restricted stock units vest over time, and a portion of the shares are withheld to cover tax liabilities.
• No specific comparable companies or projects are relevant for this routine insider transaction.

Related Party Transactions

• The transaction involves equity compensation for an officer, which is a related party transaction, but it is a standard, pre-approved compensation event rather than an unusual dealing.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine compensation event. It reflects the ongoing alignment of executive incentives with company performance.
• Employees: Demonstrates the company's commitment to its equity compensation plans for key personnel.

Next Steps

• No specific future actions, events, or milestones for the company are mentioned in this Form 4 filing, beyond the completion of the RSU vesting schedule.

Key Dates

Recommendation

This Form 4 filing reports a routine insider transaction involving the vesting of restricted stock units and subsequent tax withholding. It does not provide new information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals rather than this specific filing.

Keywords

Neurocrine Biosciences, NBIX, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Ingrid Delaet, Chief Regulatory Officer, Equity Compensation, Tax Withholding